



Financial Tear Sheet

Corporate Profile

We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Our BioSeizer lipid formulation technology enables both local sustained release and fast onset of APIs at the site of disease or injury with increased pharmacokinetic (PK) control, made possible by customization of lipid layers. BioSeizer is utilized in our TLC599, TLC399 and TLC590 programs. Our NanoX active drug loading technology enables better toxicity profiles, potential for reduced dosing frequency, and enhanced distribution of liposome-encapsulated APIs to the desired site. We believe NanoX is capable of loading over 50 various compounds and is applied to our TLC178 program.

We believe our technologies can be used with a broad range of APIs and enable a simplified and scalable manufacturing process. Because our product candidates use already approved APIs, we are eligible to utilize the streamlined 505(b)(2) regulatory pathway for approval in the United States. We have used our proprietary technology platforms to assemble a diverse product candidate portfolio that targets significant areas of unmet medical need in pain management, ophthalmology and oncology.

Our team has over 150 years of domestic and global experience in lipids and other life sciences products and drug development expertise. Their accomplishments include gaining the approval of two generic lipid formulation products marketed in Asia. We are headquartered in Taipei, Taiwan, with offices in Hsinchu, Hong Kong, Leiden, Melbourne, Shanghai, South San Francisco and Tokyo.

Stock Information

Could not find file '\\pro.dianum.io\irwebpro\content3\IRXMLDATA\25\254691\Quotes.xml'.

Could not find file '\\pro.dianum.io\irwebpro\content3\IRXMLDATA\25\254691\Quotes.xml'.

Primary IR Contact

Dawn Chi
Corporate Communications
TLC
Phone: +886 (0)2 2655 7377
E-mail: ir@tlcbio.com

Julia Balanova
Vice President
Solebury Trout
Phone: +1 646 378 2936
E-mail:
jbalanova@troutgroup.com

Recent News & Upcoming Events

2019-01-25
TLC Appoints George Spencer-Green, MD, MS, as Chief Medical Officer

2019-01-22
EMA Grants Orphan Drug Designation to TLC178 for the Treatment of Soft Tissue Sarcoma

2019-01-02
Taiwan Liposome Company to Attend 37th Annual J.P. Morgan Healthcare conference

Date	Title
2019-02-27 through 2019-02-28	BTIG Annual Healthcare Conference Location Snowbird, Utah

SEC Filings

Filing Date	Form
2019-02-19	SC 13D
2019-02-14	SC 13G
2019-02-01	6-K
2019-01-03	6-K

Corporate Governance

Keelung Hong, Ph.D.	Founder, Chairman & CEO
George Yeh, M.B.A.	President
Nicole Lin, M.B.A.	Vice President
Yunlong Tseng, Ph.D.	Vice President, Research & Development
Wenji Chen, Ph.D., M.B.A.	Vice President, Corporate Development
Hung Wei Chih, Ph.D.	Vice President - Manufacturing Development Division
Sheue Fang Shih, Ph.D.	Senior Director, Product Development
Carl Brown, Ph.D.	Director, Product Development
Cynthia Lin	Director of Clinical Operations, Clinical Development, Product Development
Terry Tai, M.D.	Director, Portfolio & Strategy
Bella Kuo	Director, Quality Assurance
Wayne Liao, Ph.D.	Director of Operations, TLC United States